Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Rosuvastatin Calcium prices in Germany, the highest-cost reporting region, fell 4.2% in Q2 2026 to USD 158,000.00/KG from USD 165,000.00/KG in Q1, extending a sustained decline that has persisted through most of the period covered in this report. Indian prices, the most closely watched benchmark for this widely used cholesterol-lowering statin ingredient, fell 4.8% to USD 138,000.00/KG, continuing a decline that has taken this market down roughly 23 percent from its Q1 2025 starting point. Globally, the average fell from USD 150,380.00/KG in Q1 to USD 143,600.00/KG in Q2, a 4.5% decline, with the softening concentrated in the second half of the observed period. For H2 2026, a global average of USD 116,000.00-155,000.00/KG is expected, with the projected Indian benchmark in a USD 129,000.00-144,000.00/KG band pointing to further softening.
Rosuvastatin Calcium is the active pharmaceutical ingredient in a widely used cholesterol-lowering statin medicine, working as an HMG-CoA reductase inhibitor that blocks an enzyme the body uses to make cholesterol, and it is prescribed to reduce the risk of heart attack and stroke. As a high-volume generic ingredient, it sits in the regulated fine-chemicals bucket, where quality compliance matters as much as cost. Steady prescription demand makes this ingredient a staple of generic drug supply, with India a major source of production and export, given the country's low-cost manufacturing base and deep generic statin manufacturing expertise. Intensifying generic competition following the original patent expiry has structurally pressured pricing, impacting overall market revenue while expanding patient access. API intermediate feedstock costs, generic drug competition intensity, and cardiovascular treatment prescription demand are what drive prices in this market.
The outlook for Rosuvastatin Calcium through H2 2026 points to further softening, with the projected Indian benchmark in a USD 129,000.00-144,000.00/KG band based on available data. Intensifying generic competition, alongside regulatory pressures and payer negotiations tied to the competitive landscape following the original patent expiry, is expected to continue weighing on pricing even as steady prescription demand from an aging population and rising cardiovascular disease awareness supports underlying volume.
The main upside risk is a tightening of API intermediate feedstock availability or a consolidation among generic manufacturers reducing competitive pricing pressure, which could slow or reverse the current decline. The main downside risk is a further intensification of generic competition combined with continued regulatory and payer pricing pressure, which could extend the softening trend beyond the currently projected range.
| Region | 2026 Price Range (USD/MT) | Outlook |
| Global Average | 116,000.00 - 155,000.00 | Intensifying generic competition points to further softening |
| Germany | 138,000.00 - 172,000.00 | Established European formulator base sustains the highest cost |
| United States | 128,000.00 - 162,000.00 | Steady cardiovascular prescription demand supports this market |
| India | 129,000.00 - 144,000.00 | Central global generic supply hub tracks the broader decline closely |
| China | 108,000.00 - 136,000.00 | Large-scale generic production keeps this the most affordable market |
German Rosuvastatin Calcium prices averaged USD 158,000.00/KG in Q2 2026, the highest of any region tracked here, down 4.2% from USD 165,000.00/KG in Q1, extending a sustained decline tied to intensifying generic competition.
Why did the price of Rosuvastatin Calcium change in Q2 2026 in Germany?
Intensifying generic competition, alongside regulatory pressures and payer negotiations tied to the competitive landscape following the original patent expiry, continued weighing on this market even as it remained the highest-priced region tracked in this report.
US prices averaged USD 149,000.00/KG in Q2 2026, down 4.5% from USD 156,000.00/KG in Q1, tracking the broader global softening trend.
Why did the price of Rosuvastatin Calcium change in Q2 2026 in the United States?
Generic competition has intensified, impacting overall market revenue while expanding patient access, with pricing subject to regulatory pressures, payer negotiations, and the competitive landscape.
Indian prices averaged USD 138,000.00/KG in Q2 2026, down 4.8% from USD 145,000.00/KG in Q1, continuing a decline that has taken this central global supply hub down roughly 23 percent from its Q1 2025 starting point.
Why did the price of Rosuvastatin Calcium change in Q2 2026 in India?
As a major source of production and export for this generic ingredient, India's pricing continued tracking the broader global decline closely, with the market's central role in global supply meaning shifts here reverberate across other regions.
Chinese prices, the lowest of the four regions, averaged USD 125,000.00/KG in Q2 2026, down 4.6% from USD 131,000.00/KG in Q1, tracking the broader global generic competition pressure.
Why did the price of Rosuvastatin Calcium change in Q2 2026 in China?
Large-scale generic API production capacity continued keeping Chinese offers the most competitive of any region tracked here, even as the broader generic competition pressure pushed prices lower across every region.
German prices fell 9.3% in Q1 2026 to USD 165,000.00/KG from USD 182,000.00/KG in Q4 2025, extending the sustained decline recorded through most of 2025.
Why did the price of Rosuvastatin Calcium change in Q1 2026 in Germany?
Rosuvastatin calcium prices fell over the period, with the decline concentrated in the second half, as generic competition continued intensifying and impacting overall market revenue even as patient access expanded.
US prices fell 9.8% in Q1 2026 to USD 156,000.00/KG from USD 173,000.00/KG in Q4 2025, tracking the broader global softening.
Why did the price of Rosuvastatin Calcium change in Q1 2026 in the United States?
Pricing continued to be subject to regulatory pressures, payer negotiations, and the competitive landscape, with generic competition having intensified following the patent expiry of the original branded product by the innovator company.
Indian prices fell 10.5% in Q1 2026 to USD 145,000.00/KG from USD 162,000.00/KG in Q4 2025, with the decline concentrated in the second half of 2025 and continuing into early 2026.
Why did the price of Rosuvastatin Calcium change in Q1 2026 in India?
The India benchmark eased from USD 189.00/KG in Q1 2025 to USD 162.00/KG by Q4 2025 and USD 145.00/KG in Q1 2026, a decline of about 23 percent from the first quarter of 2025, concentrated in the second half of the year.
Chinese prices fell 10.3% in Q1 2026 to USD 131,000.00/KG from USD 146,000.00/KG in Q4 2025, tracking the broader global generic competition pressure.
Why did the price of Rosuvastatin Calcium change in Q1 2026 in China?
Steady prescription demand kept this ingredient a staple of generic drug supply even as intensifying generic competition, tied to the competitive landscape following the original patent expiry, continued pressuring pricing across every region tracked in this report.
Global Rosuvastatin Calcium prices edged up modestly through the first half of 2025 before declining steadily and substantially through the remainder of the period covered in this report, with the decline concentrated in the second half of 2025 and continuing into 2026 as intensifying generic competition and regulatory and payer pricing pressure weighed on this high-volume generic ingredient.
| Quarter | Price (USD/MT) | QoQ Change | Direction |
| Q2 2026 | 143,600.00 | -4.5% | ↓ Falling |
| Q1 2026 | 150,380.00 | -9.9% | ↓ Falling |
| Q4 2025 | 166,940.00 | -4.1% | ↓ Falling |
| Q3 2025 | 174,000.00 | -10.6% | ↓ Falling |
| Q2 2025 | 194,560.00 | - | — Stable |
| Q3 2026 | In Progress | - | — In Progress |
Rosuvastatin Calcium declined sharply across every market covered in this report through 2025, with prices edging up modestly in the first half before falling substantially in the second, as intensifying generic competition and regulatory and payer pricing pressure combined to pull this high-volume cardiovascular API down more than 13 percent for the full year across every region tracked.
German prices declined from about USD 210,000.00/KG in Q1 2025 to USD 182,000.00/KG by Q4, down roughly 13.3%, before the continued decline that followed into 2026.
US prices declined from about USD 200,000.00/KG in Q1 2025 to USD 173,000.00/KG by Q4, down roughly 13.5%, tracking the broader generic competition pressure.
Indian prices declined from about USD 189,000.00/KG in Q1 2025 to USD 162,000.00/KG by Q4, down roughly 14.3%, the steepest annual decline of the four regions, with the decline concentrated in the second half of the year.
Chinese prices declined from about USD 170,000.00/KG in Q1 2025 to USD 146,000.00/KG by Q4, down roughly 14.1%, tracking the broader global generic competition trend.
Expert Market Research: Your Source for Real-Time Rosuvastatin Calcium Price Intelligence
Expert Market Research tracks Rosuvastatin Calcium prices continuously across every major producing and consuming region, combining API intermediate feedstock cost data, generic drug competition intensity signals, and cardiovascular treatment prescription demand trends into a single, regularly updated view of the market. Our team can help your procurement function benchmark current offers, plan purchases around the sustained decline covered in this report, and build a defensible view of where this essential cholesterol-lowering API is headed next. Reach out to our team for a tailored briefing or a deeper look at any of the regional markets covered here.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
It is the active pharmaceutical ingredient in a widely used cholesterol-lowering statin medicine, working as an HMG-CoA reductase inhibitor to reduce the risk of heart attack and stroke.
The Q2 2026 global average was USD 143,600.00/KG, ranging from USD 125,000.00/KG in China to USD 158,000.00/KG in Germany.
The global average fell from USD 166,940.00/KG in Q4 2025 to USD 150,380.00/KG in Q1 2026 and then to USD 143,600.00/KG in Q2, continuing a sustained decline concentrated in the second half of 2025 and into 2026.
Generic competition has intensified following the original patent expiry, impacting overall market revenue while expanding patient access, with pricing subject to ongoing regulatory pressures and payer negotiations.
The global average is expected in the USD 116,000.00-155,000.00/KG range, with the projected Indian benchmark in a USD 129,000.00-144,000.00/KG band pointing to further softening.
China holds the lowest cost among the regions tracked here given large-scale generic production, while Germany carries the highest cost given its established European formulator base.
This report is updated monthly. For real-time pricing intelligence, connect with the Expert Market Research team.
API intermediate feedstock costs, generic drug competition intensity, and cardiovascular treatment prescription demand.
India is a major source of production and export for this generic ingredient, given its low-cost manufacturing base, with China, Germany, and the United States also significant producing and consuming markets.
Buyers can monitor generic competition intensity and regulatory pricing pressure trends given their outsized influence on this market, time forward purchases around the quarterly breakdowns in this report, and benchmark supplier quotes against the tracked price ranges given the scale of the ongoing decline.
One Year Subscription
One Year Subscription
USD 799
USD 699
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.